EVI1 Promotes the Proliferation and Invasive Properties of Human Head and Neck Squamous Cell Carcinoma Cells
- PMID: 35162973
- PMCID: PMC8835242
- DOI: 10.3390/ijms23031050
EVI1 Promotes the Proliferation and Invasive Properties of Human Head and Neck Squamous Cell Carcinoma Cells
Abstract
Head and neck squamous cell carcinoma (HNSCC) is a frequent malignancy with a poor prognosis. So far, the EGFR inhibitor cetuximab is the only approved targeted therapy. A deeper understanding of the molecular and genetic basis of HNSCC is needed to identify additional targets for rationally designed, personalized therapeutics. The transcription factor EVI1, the major product of the MECOM locus, is an oncoprotein with roles in both hematological and solid tumors. In HNSCC, high EVI1 expression was associated with an increased propensity to form lymph node metastases, but its effects in this tumor entity have not yet been determined experimentally. We therefore overexpressed or knocked down EVI1 in several HNSCC cell lines and determined the impact of these manipulations on parameters relevant to tumor growth and invasiveness, and on gene expression patterns. Our results revealed that EVI1 promoted the proliferation and migration of HNSCC cells. Furthermore, it augmented tumor spheroid formation and the ability of tumor spheroids to displace an endothelial cell layer. Finally, EVI1 altered the expression of numerous genes in HNSCC cells, which were enriched for Gene Ontology terms related to its cellular functions. In summary, EVI1 represents a novel oncogene in HNSCC that contributes to cellular proliferation and invasiveness.
Keywords: EVI1; MECOM; PRDM3; cell proliferation; gene expression regulation; lymphatic metastasis; molecular targeted therapy; neoplasm metastasis; squamous cell carcinoma of head and neck.
Conflict of interest statement
A.S.B. has received research support from Daiichi Sankyo and Roche; honoraria for lectures, consultation, or advisory board participation from Roche, Bristol-Meyers Squibb, Merck, Daiichi Sankyo, and AstraZeneca, as well as travel support from Roche, Amgen, and AbbVie. T.F. has received research grants from Merck Sharp & Dohme, and Merck KGaA and honoraria from Merck Sharp & Dohme, Roche, Pfizer, Boehringer Ingelheim, Sanofi, Accord, Merck KGaA, Amgen, and Bristol Myers Squibb. All other authors declare that they do not have any conflict of interest.
Figures






Similar articles
-
EVI1 as a Marker for Lymph Node Metastasis in HNSCC.Int J Mol Sci. 2020 Jan 28;21(3):854. doi: 10.3390/ijms21030854. Int J Mol Sci. 2020. PMID: 32013033 Free PMC article.
-
HOXB5 acts as an oncogenic driver in head and neck squamous cell carcinoma via EGFR/Akt/Wnt/β-catenin signaling axis.Eur J Surg Oncol. 2020 Jun;46(6):1066-1073. doi: 10.1016/j.ejso.2019.12.009. Epub 2019 Dec 12. Eur J Surg Oncol. 2020. PMID: 31864826
-
Aberrant overexpression of transcription factor Forkhead box D1 predicts poor prognosis and promotes cancer progression in HNSCC.BMC Cancer. 2021 Nov 12;21(1):1205. doi: 10.1186/s12885-021-08868-4. BMC Cancer. 2021. PMID: 34772357 Free PMC article.
-
Nicotine promotes lymph node metastasis and cetuximab resistance in head and neck squamous cell carcinoma.Int J Oncol. 2019 Jan;54(1):283-294. doi: 10.3892/ijo.2018.4631. Epub 2018 Nov 12. Int J Oncol. 2019. PMID: 30431077
-
A Study on the Correlations of the miR-31 Expression with the Pathogenesis and Prognosis of Head and Neck Squamous Cell Carcinoma.Cancer Biother Radiopharm. 2019 Apr;34(3):189-195. doi: 10.1089/cbr.2018.2621. Epub 2019 Jan 10. Cancer Biother Radiopharm. 2019. PMID: 30628842
Cited by
-
The C. elegans anchor cell: A model to elucidate mechanisms underlying invasion through basement membrane.Semin Cell Dev Biol. 2024 Feb 15;154(Pt A):23-34. doi: 10.1016/j.semcdb.2023.07.002. Epub 2023 Jul 6. Semin Cell Dev Biol. 2024. PMID: 37422376 Free PMC article. Review.
-
Epigenetic targeting of MECOM/KRAS axis by JIB-04 impairs tumorigenesis and cisplatin resistance in MECOM-amplified ovarian cancer.Cell Death Discov. 2025 Jul 15;11(1):326. doi: 10.1038/s41420-025-02618-2. Cell Death Discov. 2025. PMID: 40664642 Free PMC article.
-
ImaGene: a web-based software platform for tumor radiogenomic evaluation and reporting.Bioinform Adv. 2022 Nov 10;2(1):vbac079. doi: 10.1093/bioadv/vbac079. eCollection 2022. Bioinform Adv. 2022. PMID: 36699376 Free PMC article.
-
SKA1 promotes oncogenic properties in oral dysplasia and oral squamous cell carcinoma, and augments resistance to radiotherapy.Mol Oncol. 2025 Apr;19(4):1054-1074. doi: 10.1002/1878-0261.13780. Epub 2024 Dec 10. Mol Oncol. 2025. PMID: 39656562 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous